PDCD1 and gastric cancer: In a Chinese cohort of 636 MSS/EBV-negative GC patients who were treated with anti-PD-1/PD-L1 therapy, H. pylori-positive patients had significantly longer immune-related-PFS and -OS compared to H. pylori-negative [39].